Methods | D: crossover C: unclear B: unclear WD: 7/38 J: 1‐0‐0 DU: ‐/2x8w (unclear whether washout)/‐ | |
Participants | N: 38/31 D: 7 migraine with, 24 without aura C: unclear F: unclear A: 17‐53 years DU: mean 14 years S: unclear, Israel | |
Interventions | P: 160 mg (long‐acting) C: Placebo | |
Outcomes | R: not reported F: 3.23 vs. 5.56 attacks (p = 0.014; no variance data presented) AU: not reported HI: not reported AEs: not reported Dropouts‐AEs: not reported V: + | |
Notes | Available only as an abstract | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |